Patients age @ years with locally advanced , metastatic , or recurrent advanced nonsquamous non-small-cell lung cancer ( NSCLC ) were randomly assigned to receive carboplatin ( area under the curve , @ ) intravenously and paclitaxel ( @ mg/m ( @ ) ) intravenously ( CP ) on day @ of each @-week cycle , for six cycles , plus placebo ( Pl + CP ) or bevacizumab ( B+CP ) @ mg/kg intravenously , on day @ of each cycle , until progression , unacceptable toxicity , or death .